R.H. Bluestein & Co’s Teradyne TER Stock Holding History

R.H. Bluestein & Co’s Portfolio TER Stock Details TER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,000	Closed	-$338K	–	366
2020 Q2	$338K	Hold	4,000	–	–	0.02%	210
2020 Q1	$217K	Buy	+4,000	New	+$254K	0.02%	237
2018 Q2	–	Sell	-5,000	Closed	-$229K	–	331
2018 Q1	$229K	Hold	5,000	–	–	0.01%	296
2017 Q4	$209K	Buy	+5,000	New	+$206K	0.01%	300

Other funds holding TER

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

R.H. Bluestein & Co's TER Position: Q3 2020 in Review

R.H. Bluestein & Co sold out of Teradyne (TER) in Q3 2020, closing a stake of 4,000 shares — an estimated $338K sold.

R.H. Bluestein & Co first reported a position in TER in Q4 2017 and held it in 4 quarters. The position peaked at $338K in Q2 2020. 582 funds tracked by Wall St. Rank hold TER as of Q3 2020.

R.H. Bluestein & Co reported no remaining Teradyne position as of Q3 2020 after selling out during the quarter.
R.H. Bluestein & Co sold 4,000 Teradyne shares in Q3 2020, an estimated $338K.
R.H. Bluestein & Co first reported a position in Teradyne in Q4 2017 and held it in 4 quarters.
R.H. Bluestein & Co's Teradyne position peaked at $338K in Q2 2020.
582 funds tracked by Wall St. Rank held Teradyne as of Q3 2020.

Based on R.H. Bluestein & Co's 13F filing for Q3 2020, filed 12 Nov 2020.